Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure

Biochemical Pharmacology

Volumn 65, Issue 11, 2003, Pages 1867-1874

  Hynson, Robert M G ^a   Wouters, Johan ^b   Ramsay, Rona R ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b Campus du CERIA   (Belgium)

Author keywords

Difference spectra; Flavin; Molecular orbital calculations; Monoamine oxidase; Reduction; Structure activity relationship

Indexed keywords

DITHIONITE; LUMIFLAVINE; MONOAMINE OXIDASE A INHIBITOR; PIRLINDOLE; QUERCETIN; SEMIQUINONE;

ARTICLE; BINDING AFFINITY; CHEMICAL BOND; DRUG EFFECT; ENZYME ACTIVITY; KINETICS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REDUCTION; SPECTRUM; THERMODYNAMICS; TITRIMETRY;

EID: 0037716398     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00185-0     Document Type: Article

References (27)

1. Wouters J. Structural aspects of monoamine oxidase and its reversible inhibition. Curr. Med. Chem. 5:1998;137-162.
2. Kalgutkar A.S., Dalvie D.K., Castagnoli N., Taylor T.J. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol. 14:2001;1139-1162.
3. Nandigama R.K., Edmondson D.E. Structure-activity relations in the oxidation of phenethylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry. 39:2000;15258-15265.
4. Miller J.R., Edmondson D.E. Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry. 38:1999;13670-13683.
5. Medvedev A.E., Ivanov A.S., Veselovsky A.V., Skvortsov V.S., Archakov A.I. QSAR analysis of indole analogues as monoamine oxidase inhibitors. J. Chem. Inf. Comput. Sci. 36:1996;664-671.
6. Gnerre C., Catto M., Leonetti F., Weber P., Carrupt P.A., Altomare C., Carotti A., Testa B. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J. Med. Chem. 43:2000;4747-4758.
7. Vallejos G., Rezende M.C., Cassels B.K. Charge-transfer interactions in the inhibition of MAO-A by phenylisopropylamines - a QSAR study. J. Comput. Aided Mol. Des. 16:2002;95-103.
8. Codoner A., Medina P., Ortiz C., Jover E. Spectroscopic study of molecular associations between riboflavin and some (dihydro) beta-carboline derivatives. Spectroc. Acta Pt. A: Mol. Biomol. Spectrosc. 49:1993;321-327.
9. Moureau F., Wouters J., Depas M., Vercauteren D.P., Durant F., Ducrey F., Koenig J.J., Jarreau F.X. A reversible monoamine-oxidase inhibitor toloxatone - comparison of its physicochemical properties with those of other inhibitors including brofaromine, harmine, R40519 and moclobemide. Eur. J. Med. Chem. 30:1995;823-838.
10. Moureau F., Wouters J., Vercauteren D.P., Collin S., Evrard G., Durant F., Ducrey F., Koenig J.J., Jarreau F.X. A reversible monoamine-oxidase inhibitor, toloxatone-spectrophotometric and molecular-orbital studies of the interaction with flavin adenine-dinucleotide (FAD). Eur. J. Med. Chem. 29:1994;269-277.
11. Niemz A., Rotello V.M. From enzyme to molecular device. Exploring the interdependence of redox and molecular recognition. Acc. Chem. Res. 32:1999;44-52.
12. Kim H., Sablin S.O., Ramsay R.R. Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch. Biochem. Biophys. 337:1997;137-142.
13. Binda C., Newton-Vinson P., Hubalek F., Edmondson D.E., Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. 9:2002;22-26.
14. Ramsay R.R., Hunter D.J.B. Inhibitors alter the spectrum and redox properties of monoamine oxidase A. BBA Proteins Proteomics. 1601:2002;178-184.
15. Tan A.K., Weyler W., Salach J.I., Singer T.P. Differences in substrate specificities of monoamine oxidase A from human liver and placenta. Biochem. Biophys. Res. Commun. 181:1991;1084-1088.
16. Weyler W., Salach J.I. Purification and properties of mitochondrial monoamine-oxidase type-A from human placenta. J. Biol. Chem. 260:1985;3199-3207.
17. Sablin S.O., Ramsay R.R. Substrates but not inhibitors alter the redox potentials of monoamine oxidases. Antioxid. Redox Signal. 3:2001;723-729.
18. Sablin S.O., Ramsay R.R. Monoamine oxidase contains a redox-active disulfide. J. Biol. Chem. 273:1998;14074-14076.
19. Laaksonen L. A graphics program for the analysis and display of molecular-dynamics trajectories. J. Mol. Graph. 10:1999;33.
20. McEwen C.M. Jr., Sasaki G., Jones D.C. Human liver mitochondrial monoamine oxidase. II. Determinants of substrate and inhibitor specificities. Biochemistry. 8:1969;3952-3962.
21. Veselovsky A.V., Medvedev A.E., Tikhonova O.V., Skvortsov V.S., Ivanov A.S. Modeling of substrate-binding region of the active site of monoamine oxidase A. Biochemistry (Mosc.). 65:2000;910-916.
22. Ramsay R.R. Kinetic mechanism of monoamine oxidase-A. Biochemistry. 30:1991;4624-4629.
23. Ramsay R.R., Gravestock M.B. Monoamine oxidases: to inhibit or not to inhibit. Mini Rev. Med. Chem. 3:2003;129-136.
24. Medvedev A.E., Veselovsky A.V., Shvedov V.I., Tikhonova O.V., Moskvitina T.A., Fedotova O.A., Axenova L.N., Kamyshanskaya N.S., Kirkel A.Z., Ivanov A.S. Inhibition of monoamine oxidase by pirlindole analogues: 3D-QSAR and CoMFA analysis. J. Chem. Inf. Comput. Sci. 38:1998;1137-1144.
25. Medvedev A.E., Ramsay R.R., Ivanov A.S., Veselovsky A.V., Shvedov V.I., Tikhonova O.V., Vintem A.-P.B., Davidson C.K., Moskvitina T.A., Fedotova O.A., Axenova L.N. Inhibition of monoamine oxidase by pirlindole analogs: 3-D QSAR analysis. Neurobiology. 7:1999;151-158.
26. Wouters J., Perpète P., Norberg B., Evrard G., Durant F. Molecular structure of lumiflavin hydrochloride hydrate: comparison with the hydrogen bonding at the cofactor of flavoproteins. J. Chem. Cryst. 24:1994;607-614.
27. Wouters J., Evrard G., Durant F. Molecular structure of lumiflavinium (7,8,10-trimethylisoalloxazine)nitrate. Acta Crystallogr. C51:1995;1223-1227.